Caricamento...
Dysregulation of mTOR activity through LKB1 inactivation
Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either du...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Sun Yat-sen University Cancer Center
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845579/ https://ncbi.nlm.nih.gov/pubmed/23668926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.013.10086 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|